Dawaa Reference

Clinical reference

Malignant neoplasm of the musculoskeletal system

Treatment options, dosing, cautions and Egyptian brands from the shipped Dawaa Reference card.

Evidence status

Checked against the sources named below

Sources3 sources

ICPC-3 (WONCA International Classification of Primary Care, 3rd edition) class LD25 - condition scope only, no dose · No dose - referral pathway, no medicine given in primary care · Osteosarcoma (Osteogenic Sarcoma) - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK563177/

Verified against1 document
  • No dose - referral pathway, no medicine given in primary care

Verified date2026-08

1

NO DRUG THERAPY IN PRIMARY CARE (REFERRAL & ADVICE)

1st line
Adult dose and duration

A rare but serious malignancy (osteosarcoma, fibrosarcoma) needing oncology and orthopaedic-oncology management; the GP's role is prompt recognition of red flags, pain relief, and urgent referral. - Refer, with advice

Paediatric dose

Children follow the same pathway: recognise and refer. No primary-care medicine is implied.

Dose source

No dose - referral pathway, no medicine given in primary care

Why

A rare but serious malignancy (osteosarcoma, fibrosarcoma) needing oncology and orthopaedic-oncology management; the GP's role is prompt recognition of red flags, pain relief, and urgent referral.

Cautions
  • Unexplained bone pain especially at night, palpable enlarging mass, unexplained fracture, unexplained weight loss.
  • Rare in Egyptian primary care.
  • No medicine is prescribed for this in primary care - this entry is for recognition and referral. Anything given is decided by the service it is referred to.

Prices are indicative (dataset snapshot 2026-06); verify with the pharmacy.